AtriCure Issues 2026 Revenue Guidance of $600M-$610M
ATRC is trading near its 52-week low of $26.62 (11% above the low) on elevated volume (1.9× avg).
Summary
AtriCure, Inc. has provided full-year 2026 revenue guidance, projecting sales to be in the range of $600 million to $610 million. This guidance follows the company's announcement of strong first-quarter 2026 financial results, as detailed in an 8-K filing earlier today. The specific revenue outlook for the full year is a critical data point for investors, offering clarity on management's expectations for future performance and serving as a key input for financial modeling. Traders will be watching subsequent earnings reports for progress against this guidance and any potential revisions.
At the time of this announcement, ATRC was trading at $29.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $26.62 to $43.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.